This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Mylan gets Kinney Drugs' antitrust claims over EpiPen dismissed

( July 26, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Mylan has won the dismissal of Kinney Drugs’ antitrust claims over EpiPen. US District Judge Daniel D. Crabtree concluded that Kinney lacks standing as an indirect purchaser and its assignment of rights from McKesson does not grant it standing because the core of Kinney’s case does not relate to the delay of generic competition, only tying, as required under the assignment.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections